Study Stopped
Funding for secondary outcomes in fecal microbiome is not solved
SREBF1 Polymorphism and Egg Yolk on Cardiovascular Disease Risk in Healthy Young Adults: a Randomised, Two-period, Single Blinded, Crossover Trial
1 other identifier
interventional
64
1 country
1
Brief Summary
Our previous analysis showed that sterol regulatory element binding protein gene (SREBF1) rs2236513/rs2297508/rs4925119 polymorphism modulated the relation between dietary cholesterol and serum low density lipoprotein cholesterol /serum total cholesterol. This study aims to confirm and extend this finding by characterizing the effects of cholesterol from egg yolks on lipid profiles in healthy young adults with different SREBF1 genetic makeup. 32 SREBF1 C/G/G minor allele carriers at rs2236513/rs2297508/rs4925119 and 32 SREBF1 AA/CC/AA major homozygotes at rs2236513/rs2297508/rs4925119 were enrolled to test their response to egg yolks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable healthy
Started May 2019
Longer than P75 for not_applicable healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 14, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 12, 2020
CompletedFirst Submitted
Initial submission to the registry
June 30, 2021
CompletedFirst Posted
Study publicly available on registry
July 23, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedMay 15, 2025
May 1, 2024
8 months
June 30, 2021
May 13, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in serum lipids
Serum lipids including serum total cholesterol, LDL-C, HDL-C and LDL-C/HDL-C, triglycerides
Week 0, week 4, week 8, week 16
Study Arms (2)
Group A
EXPERIMENTALGroup A was consisted of 16 rs2236513/rs2297508/rs4925119 C/G/G carriers and 16 AA/CC/AA homozygotes. And it was first assigned egg yolk intervention during intervention period 1, and then macronutrient equivalent control during intervention period 2
Group B
OTHERGroup B was also consisted of 16 rs2236513/rs2297508/rs4925119 C/G/G carriers and 16 AA/CC/AA homozygotes. It was first assigned macronutrient equivalent control during intervention period 1, and then egg yolk during intervention period 2
Interventions
Two egg yolks/day was designed for the study. However, uneven egg sizes during period 1 made the intervention unable to achieve the protocol's recommended cholesterol intake level, and the intervention was modified in period 2 to be 0.8 g egg yolk/day/kg body weight. This dosage was calculated by dividing the 35 g egg yolk with the lightest weight among the volunteers, which was 45 kg. This provides a more consistent cholesterol intake between persons as the egg yolk dosage is standardized for persons with different weights.
The macronutrients equivalent control group was served 42 g egg white cooked with 10 g olive oil, designed to best imitate the energy and macronutrients of 35 g egg yolk (energy 119 kcal, protein 5 g, fat 10 g, carbohydrate 1 g) since the average weight of two large egg yolk was presumed to be 35 g. As an egg yolk dose of 0.8 g egg yolk per kg body weight per day was served during the intervention period 2, the macronutrients equivalent control was likewise adjusted as follow: subjects who weighed less than 55 kg were served 51 g egg white cooked with 12 g olive oil, which is equivalent to 40 g egg yolk; those who weighed from 55 kg to 65 kg were served 61 g egg white cooked with 14 g olive oil, which is equivalent to 48 g egg yolk; and those who weighed more than 65 kg were served 71 g egg white cooked with 17 g olive oil, which is equivalent to 56 g egg yolk.
Eligibility Criteria
You may qualify if:
- SREBF1 C/G/G minor allele carriers and AA/CC/AA major homozygotes at rs2236513/rs2297508/rs4925119, age 18-25 years, body mass index (BMI) 18\~23.9 kg/m2 , blood pressure within normal ranges (Systolic blood pressure \< 140mmHg, diastolic blood pressure \< 90mmHg), lipid profiles within normal ranges according to test kit instructions (fasting serum triglycerides \< 1.7mmol/L, fasting serum total cholesterol \< 5.2 mmol/L, fasting serum low density lipoprotein cholesterol (LDL-C) \< 3.12 mmol/L, fasting serum high density lipoprotein cholesterol (HDL-C) \>1.04 mmol/L ), liver and kidney functions within normal ranges according to test kit instructions (alanine aminotransferase (ALT) 9\~50 U/L for male, 7\~40 U/L for female; aspartate transaminase (AST) 15\~40 U/L for male, 13\~35 U/L for female; creatinine 62\~115 μmol/L for male, 53\~97 μmol/L for female; blood urea nitrogen (BUN), 1.43\~7.14 mmol/L), both parents are Chinese Han nationality, willing to eat two or more eggs, and willing to maintain "Three Low Diet" except when they were given egg yolks during the study.
You may not qualify if:
- History of diabetes, cancer, stroke, heart disease or any other known diseases, allergic to eggs, or having habits such as drinking or smoking.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Shandong Universitylead
- Chinese Nutrition Societycollaborator
- Fudan Universitycollaborator
Study Sites (1)
Shandong University
Jinan, Shandong, 250012, China
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Shixiu Zhang, Ph. D.
Shandong University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- CARE PROVIDER
- Masking Details
- Masking was applied for those who collected blood samples, physical examination data, and assessed laboratory outcomes. People who were masked did not participate in the routine management meetings of the trial.
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 30, 2021
First Posted
July 23, 2021
Study Start
May 14, 2019
Primary Completion
January 12, 2020
Study Completion
December 1, 2025
Last Updated
May 15, 2025
Record last verified: 2024-05
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- All IPD that underlie results in a publication will be shared as claimed by the journal that the publication is published.
- Access Criteria
- Can access data by contacting Shixiu Zhang.
All IPD that underlie results in a publication.